Login to Your Account

Symphogen, Genentech Sign Antibodies Deal Worth $330M

By Catherine Hollingsworth

Wednesday, June 11, 2008
In its first major deal, Danish biotech Symphogen AS agreed to a $330 million collaboration with Genentech Inc. to discover and develop antibody therapeutics against three undisclosed infectious disease targets.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription